With regard to a potential prognostic relevance of SEC62 expression, several studies reported a significant correlation of elevated Sec62 levels with poor patient prognosis in non-small cell lung cancer [328], breast cancer [334], liver cancer [322], and head and neck cancer [329,330]. This evidence concerns the gene SEC62 and non-small cell lung carcinoma.